inhibitor, a 2',3'-dideoxynucleoside, an immunomodulator, erythropoietin, ampligen, thyomodulin, thymopentin, foscarnet, ribavirin, or an inhibitor of HIV binding to CD4.

28. A method according to claim 27 [23], wherein the amount of said compound or pharmaceutically acceptable salt thereof is 20-1000 mg.

29. A method according to claim 28 [23], wherein the amount of said compound or pharmaceutically acceptable salt thereof is 50-700 mg.

31. A method according to claim 25 [30], wherein said composition contains an amount of the (+)-enantiomer of no more than 2% w/w.

37. A method according to claim 25, [for treating a mammal suffering from HIV infection comprising:

administering to said mammal a pharmaceutical composition comprising the compound (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one and a pharmaceutically acceptable carrier,]

wherein said compound is administered at a dosage of 0.1-750 mg/kg of body weight per day.

Please add the following new claims:

43. A pharmaceutical composition comprising:

a pharmaceutically acceptable carrier, the compound (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one or a pharmaceutically acceptable salt thereof, and another agent having antiviral activity

wherein the amount of the (+)-enantiomer corresponding to said compound present in said composition is no more than 5% w/w, relative to the combined weight of (-) and (+) enantiomers.

44. A composition according to claim 43, wherein said agent is an acyclic nucleoside, an interferon, a renal excretion inhibitor, a nucleoside transport inhibitor, a 2',3'-dideoxynucleoside, an immunomodulator, erythropoietin, ampligen, thyomodulin, thymopentin, foscarnet, ribavirin, or an inhibitor of HIV binding to CD4.

45. A composition according to claim 43, wherein said composition contains 10-1500 mg of said compound or pharmaceutically acceptable salt thereof.

46. A composition according to claim 45, wherein said composition contains 20-1000 mg of said compound or pharmaceutically acceptable salt thereof.

47. A composition according to claim 45, wherein said composition contains 50-700 mg of said compound or pharmaceutically acceptable salt

48. A composition according to claim 43, wherein said compound is ~~composition contains~~ (-)-*cis*-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one.

49. A composition according to claim 48, wherein said agent is an acyclic nucleoside, an interferon, a renal excretion inhibitor, a nucleoside transport inhibitor, a 2',3'-dideoxynucleoside, an immunomodulator, erythropoetin, ampligen, thyomodulin, thymopentin, foscarnet, ribavirin, or an inhibitor of HIV binding to CD4.

50. A composition according to claim 48, wherein said composition contains 1-1500 mg of said compound.

51. A composition according to claim 50, wherein said composition contains 20-1000 mg of said compound.

52. A composition according to claim 51, wherein said composition contains 50-700 mg of said compound.

53. A composition according to claim 48, wherein said composition contains an amount of the (+)-enantiomer of no more than 2% w/w.

54. A composition according to claim 53, wherein said composition contains an amount of the (+)-enantiomer of no more than 1% w/w.

55. A composition according to claim 48, wherein said composition contains an amount of the (+)-enantiomer of no more than 2% w/w.

56. A composition according to claim 55, wherein said composition contains an amount of the (+)-enantiomer of no more than 1% w/w.

57. A composition according to claim 44, wherein said agent is selected from AZT, 2'3'-dideoxycytidine, 2'3'-dideoxyadenosine, 2'3'-dideoxyinosine, 2'3'-dideoxy-hymidine, 2'3'-dideoxy-2'3'-didehydrothymidine, and 2'3'-dideoxy 2'3'-didehydrocytine.

58. A method according to claim 26, wherein said agent is selected from AZT, 2'3'-dideoxycytidine, 2'3'-dideoxyadenosine, 2'3'-dideoxyinosine, 2'3'-dideoxy-hymidine, 2'3'-dideoxy-2'3'-didehydrothymidine, and 2'3'-dideoxy 2'3'-didehydrocytine.